Nyxoah Q2 US Revenue Surges 22% as Active Implanting Accounts Double to 180 Nationwide

The Quick Take

• Nyxoah SA Q2 2026 US revenue surged 22% sequentially as active implanting accounts doubled to 180 nationwide
• The Belgian sleep apnea device maker posted strong US commercial ramp but continues to manage international market rollout timing
• Nyxoah's Genio system is gaining traction in the US hypoglossal nerve stimulation market, competing with Inspire Medical

Nyxoah SA (Nasdaq: NYXH) reported strong second-quarter 2026 commercial performance in the United States, with revenue surging 22% on a sequential basis as the number of active implanting accounts doubled to 180 locations nationwide. The acceleration reflects a broadening adoption of the company's Genio hypoglossal nerve stimulation system for obstructive sleep apnea — a rapidly growing market where Nyxoah competes primarily with Inspire Medical Systems, the established market leader. Doubling the active account base is a critical milestone, as it significantly expands the physician touchpoints generating commercial volume and reduces dependence on a small number of high-volume implanting centers.

The US commercial momentum comes at a pivotal stage for Nyxoah, which is in the process of building its commercial infrastructure from the ground up following FDA approval of the Genio system. The 22% sequential revenue growth rate indicates that the company's sales force expansion and physician training programs are translating into real commercial velocity. For medical device investors, active account growth is one of the most important leading indicators of revenue sustainability, as accounts that have been trained and have completed initial implants tend to generate steady procedure volume over time as their patient pipeline grows through physician referral networks.

Nyxoah's Q2 US strength contrasts with the more measured pace of international market expansion, where reimbursement timelines and regulatory processes in European markets have created a longer pathway to commercial scale. The company's strategic emphasis on the US market — which offers faster access to a large commercially insured patient population — appears validated by Q2 results. Investors will focus on whether the 22% sequential growth rate can be sustained or accelerated in Q3 as the account base matures and average revenue per account trends higher, which is the normal commercial development pattern for implantable medical device platforms.

Synthesized from 3 sources.